关键词： 疫情下   家政行业   发展形势   分析  

摘要： 2020年一场突如其来的疫情打乱了所有人的脚步,给全世界人民的生活带来了严重的影响。到目前为止,在中央的领导下和全国人民的共同努力下,疫情得到很好的控制。尽管如此,中国经济的增长仍然受到相当大的影响。受新冠疫情影响,由于人与人的直接接触受限,家政服务业受到较大地冲击,行业发展面临着巨大挑战,疫情的暴发也为家政服务行业提质扩容转型升级提供了新的转机,从全流程数字化改造、服务标准规范程度提升、服务人员精细化管理等方面催生了家政服务行业数字化智能化高质量发展的机遇。

关键词： 新型冠状病毒   痰液   细胞学   液基  

摘要： 随着人类社会快速发展,致病微生物也在不断演变,严重危害人类健康。新型冠状病毒肺炎[1](COVID-19)为新发急性呼吸道传染病,可以通过呼吸道飞沫传播、密切接触、密闭环境中高浓度气溶胶等传播,已成为全球性重大的公共卫生事件。面临如此严峻的疫情,给病理科痰液样本的制作带来了风险。因此如何对送检的痰样进行消毒和灭活,成为我们更为关注的问题。

关键词： Adams-Bashforth-Moulton method   COVID-19 disease   existence theorems   numerical simulations   stability analysis   uniqueness theorems  

摘要： Coronavirus infection (COVID-19) is a considerably dangerous disease with a high demise rate around the world. There is no known vaccination or medicine until our time because the unknown aspects of the virus are more significant than our theoretical and experimental knowledge. One of the most effective strategies for comprehending and controlling the spread of this epidemic is to model it using a powerful mathematical model. However, mathematical modeling with a fractional operator can provide explanations for the disease's possibility and severity. Accordingly, basic information will be provided to identify the kind of measure and intrusion that will be required to control the disease's progress. In this study, we propose using a fractional-order SEIARPQ model with the Caputo sense to model the coronavirus (COVID-19) pandemic, which has never been done before in the literature. The stability analysis, existence, uniqueness theorems, and numerical solutions of such a model are displayed. All results were numerically simulated using MATLAB programming. The current study supports the applicability and influence of fractional operators on real-world problems.

关键词： Antibodies against platelet factor 4 (PF4)   Thrombocytopenia syndrome (TTS)   Vaccination   Death   AstraZeneca   COVID-19   Forensic medicine  

摘要： We report a case of cerebral venous sinus thrombosis, bilateral adrenal hemorrhage, and thrombocytopenia in a 70-year-old man found dead. He had previously received the ChAdOx1 nCoV-19 vaccine (Vaxzevria (R), AstraZeneca) 18 days before, and had since developed unspecific and undiagnosed characteristics of what proved to be a rare case of vaccine-associated thrombocytopenia with thrombosis syndrome (TTS). He was found dead 1 week after the beginning of symptoms (day 25 post-vaccine). Autopsy yielded venous hemorrhagic infarction with the presence of thrombi within dural venous sinuses, and extensive hemorrhagic necrosis of the central part of the adrenal glands. Antibodies against platelet factor 4 (PF4) were strongly positive in postmortem fluids, as measured with an enzyme-linked immunosorbent assay (ELISA). This difficult diagnosis is usually made during the patient's lifetime. After eliminating differential diagnoses, we concluded on a fatal case of vaccine-induced immune TTS with positive anti-PF4 antibodies in cadaveric blood, 3 weeks after ChAdOx1 nCoV-19 vaccination. Specific search for anti-PF4 antibodies in cadaveric blood appears therefore paramount to assess postmortem cases of TTS associated with anti-COVID vaccines.

摘要： Background COVID-19 vaccine rollout is lagging in Africa, where there has been a high rate of SARS-CoV-2 infection. We aimed to evaluate the effect of SARS-CoV-2 infection before vaccination with the ChAdOx-nCoV19 (AZD1222) vaccine on antibody responses through to 180 days. Methods We did an unmasked post-hoc immunogenicity analysis after the first and second doses of AZD1222 in a randomised, placebo-controlled, phase 1b-2a study done in seven locations in South Africa. AZD1222 recipients who were HIV-uninfected, were stratified into baseline seropositive or seronegative groups using the serum anti-nucleocapsid (anti-N) immunoglobulin G (IgG) electroluminescence immunoassay to establish SARS-CoV-2 infection before the first dose of AZD1222. Binding IgG to spike (anti-S) and receptor binding domain (anti-RBD) were measured before the first dose (day 0), second dose (day 28), day 42, and day 180. Neutralising antibody (NAb) against SARS-CoV-2 variants D614G, beta, delta, gamma, and ***.V2, and omicron BA1 and BA.4 variants, were measured by pseudovirus assay (day 28, day 42, and day 180). This trial is registered with ***, NCT04444674, and the Pan African Clinicals Trials Registry, PACTR202006922165132. Findings Of 185 individuals who were randomly assigned to AZD1222, we included 91 individuals who were baseline seropositive and 58 who were baseline seronegative, in the final analysis. In the seropositive group, there was little change of anti-S IgG (and anti-RBD IgG) or neutralising antibody (NAb) titres at day 42 compared with at day 28. Anti-S (and anti-RBD) IgG geometric mean concentrations (GMCs) were higher throughout in the seropositive compared with the seronegative group, including at day 180 (GMCs 517middot8 [95% CI 411middot3-651middot9] vs 82middot1 [55middot2-122middot3] BAU/mL). Also D614G NAb geometric mean titres (GMTs) were higher in the seropositive group than the seronegative group, as was the percentage with titres of at least 185

关键词： Vogt-Koyanagi-Harada disease   COVID-19 vaccine   ChAdOx1 nCoV-19   mRNA-1273   Ocular adverse events  

摘要： Almost all vaccines have been reported to be associated with ocular inflamma-tion, which has caused some concern regarding global mass COVID-19 vaccination efforts. Vogt-Koyanagi-Harada disease (VKHD) is a granulomatous inflammation caused by an autoim-mune response against antigens in melanocytes, including those in the eyes. The mechanism by which COVID-19 vaccines are associated with VKHD is still unclear. Here, we report two cases of VKHD following COVID-19 vaccination. The first is a case of probable VKHD that presented with bilateral vision loss after administration of the adenovirus-vectored vaccine ChAdOx1 nCoV-19 (AstraZeneca). The condition improved after intravenous methylprednisolone 1 g daily for 3 days, followed by oral methotrexate and a slow taper of oral corticosteroids. The second case is a patient with an established diagnosis of well-controlled VKHD who developed a reactiva-tion of the disease after receiving the mRNA-based vaccine (mRNA-1273, Moderna). VKHD is a potential ocular event that could follow COVID-19 vaccination. Awareness of this association is key to early detection and treatment to prevent loss of vision. (c) 2023 Elsevier Masson SAS. All rights reserved.

关键词： SARS nCoV   SARS CoV   Sequence analysis   Insertion   Deletion   Substitution  

摘要： SARS-nCoV was identified as corona virus had spread worldwide very quickly and affected more than million people worldwide. To halt this acceleration and for efficient control the knowledge on genomic information is of utmost importance. We attempted to determine the nature of variation i.e., insertion, deletion, substitution, among structural sequences required to code for membrane, spike, nucleocapsid, envelope protein and glycosylation variation between SARS CoV and SARS nCoV spike glycoproteins, respectively. Comparative sequence analysis was performed by using retrieved sequences from the NCBI database. The analyzed sequences revealed, that the sequences coding for envelope protein show minor substituting amino acids. SARS CoV showed 94.74 percent amino acid identities with SARS nCoV amino acid sequences coding for envelope protein. In comparison to SARS nCoV, distinct amino acid residues vary in SARS CoV sequences coding for membrane, nucleocapsid, and spike proteins, respectively. S protein coding sequences of SARS CoV exhibited one deletion, six insertion and six hundred three substitutions in SARS nCoV sequence. Insertion of valine was found in receptor binding domain of SARS nCoV at position 487, and NSPR amino acid residues at position 683-686. Deletions and substitutions were also found in nucleotide sequences of strain B.1.617.2 of SARS nCoV. Additionally, binding interaction pattern of ACE2 receptor protein with original wild-type SARS-CoV-2 strain with the recently evolved Omicron variant was also evaluated. The docking results substantiated that the specific variation in binding residues is likely to impact virulence pattern of both variants.

关键词： Deep learning algorithm   2019-nCoV   Infectivity   Prediction model   Public health  

摘要： The aim is to explore the development trend of COVID-19 (Corona Virus Disease 2019) and predict the infectivity of 2019-nCoV (2019 Novel Coronavirus), as well as its impact on public health. First, the existing data are analyzed through data pre-processing to extract useful feature factors. Then, the LSTM (Long-Short Term Memory) prediction model in the deep learning algorithm is used to predict the epidemic situation in Hubei Province, outside Hubei nationwide, and the whole country, respectively. Meanwhile, the impact of intervention time changes on the epidemic situation is compared. The results show that the prediction results are almost consistent with the actual values. Specifically, Hubei Province abolishes quarantine restrictions after the Spring Festival holiday, and the first COVID-19 peak is reached in late February, while the second COVID-19 peak has been reached in early March. Finally, the cumulative number of diagnoses reaches 85,000 cases, with an increase of 15,000 cases compared with the nationwide cases outside Hubei under the continuous implementation of prevention and control measures. Under the prediction of the proposed LSTM model, if the nationwide implementation of prevention and control interventions is postponed by 5 days, the epidemic will peak in early March, and the cumulative number of diagnoses will be about 200,000;and if the intervention measures are implemented five days earlier, the epidemic will peak in mid-February, with a cumulative number of diagnoses of approximately 40,000. Meanwhile, the proposed LSTM model predicts the RMSE values of the epidemic situation in Hubei Province, outside Hubei nationwide, and the whole country as 34.63, 75.42, and 50.27, respectively. Under model comparison analysis, the prediction error of the proposed LSTM model is small and has better applicability over similar algorithms. The results show that the LSTM model is effective and has high performance in infectious disease prediction, and the res

关键词： COVID-19   Vaccine   BNT162b2   ChAdOx1 nCoV-19  

摘要： BackgroundBoth BNT162b2 (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines have shown high efficacy against COVID-19 in randomized controlled trials. However, their comparative effectiveness against COVID-19 is unclear in the real world. We evaluated the comparative effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19 in the UK general *** emulated a target trial using IQVIA Medical Research Database (IMRD), an electronic primary care database from the UK (2021). We included 1,311,075 participants, consisting of 637,549 men and 673,526 women age >= 18 years, who received vaccination with BNT162b2 or ChAdOx1 nCoV-19 between January 1 and August 31, 2021. The outcomes consisted of confirmed diagnosis of SARS-CoV-2 infection, hospitalisation for COVID-19 and death from COVID-19 in the IMRD. We performed a cox-proportional hazard model to compare the risk of each outcome variable between the two vaccines adjusting for potential confounders with time-stratified overlap weighting of propensity score (PS).ResultsDuring a mean of 6.7 months of follow-up, 20,070 confirmed SARS-CoV-2 infection occurred in individuals who received BNT162b2 vaccine (PS weighted incidence rate: 3.65 per 1000 person-months), and 31,611 SARS-CoV-2 infection occurred in those who received ChAdOx1 nCoV-19 vaccine (PS weighted incidence rate: 5.25 per 1000 person-months). The time-stratified PS weighted rate difference of SARS-CoV-2 infection for BNT162b2 group vs. ChAdOx1 nCoV-19 group was -1.60 per 1000 person-months (95% confidence interval [CI]: -1.76 to -1.43 per 1000 person-months), and the hazard ratio was 0.69 (95% CI: 0.68 to 0.71). The results were similar across the stratum of sex, age (<65 and >= 65 years), and study periods (i.e., alpha-variant predominance period and delta-variant predominance period). The PS weighted incidence of hospitalisation for COVID-19 was also lower in the BNT162b2 vaccine group than that in the ChAdOx1 va